Treatment-insulin interactions were suggestive for overall and obesity-related cancers (adjusted interaction p = 0.055 and 0.072, respectively), but no evidence of interaction was observed for non-obesity-related cancers (adjusted interaction p = 0.469). This evidence concerns the gene INS and obesity disorder.